Healthcare · Medical Specialties

Abbott Laboratories

NYSEABT ISINUS0028241000 SEC CIK0000001800 Listed on NYSE · USD

$108.65 -0.64 (-0.59%) Pre-market $110.56 (+1.16%) ≈ ₹10,197 a share

Open chart

Price, last 12 months-13.51% in a year

Key numbers

Market value: $188.18B
P/E (TTM): 40.3
Forward P/E: 19.0
EPS (TTM): $2.70
Dividend yield: 2.32%
Beta: 0.54
Day range: $107.88 – $110.78
52-week range: $81.97 – $132.03
Volume: 1,149,175
10-day avg volume: $8.74M
Revenue (TTM): $48.23B
EBITDA (TTM): $10.80B
Gross margin: 57.0%
Net margin: 9.8%
Return on equity: 9.2%
Debt / equity: 61.1%
Price / sales: 3.90
Shares out: 1.73B

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$10.24B$1.78B$1.59B

Dec 23

$9.96B$1.39B$1.23B

Mar 24

$10.38B$1.67B$1.30B

Jun 24

$10.64B$1.86B$1.65B

Sep 24

$10.97B$1.91B$9.23B

Dec 24

$10.36B$1.69B$1.33B

Mar 25

$11.14B$2.05B$1.78B

Jun 25

$11.37B$2.06B$1.64B

Sep 25

$11.46B$2.25B$1.78B

Dec 25

$11.16B$1.35B$1.08B

Mar 26

$12.59B$1.69B$928.00M

Jun 26

$13.01B$1.36B$920.00M

Sep 26

Revenue · QoQ (vs last quarter)

—-2.7%+4.1%+2.5%+3.2%-5.6%+7.6%+2.0%+0.8%-2.6%+13%+3.3%

Revenue · YoY (vs a year ago)

————+7.2%+4.0%+7.4%+6.9%+4.4%+7.8%+13%+14%

Net income · QoQ (vs last quarter)

—-23%+6.3%+26%+461%-86%+34%-7.6%+8.0%-39%-14%-0.9%

Net income · YoY (vs a year ago)

————+479%+8.2%+37%-0.1%-81%-19%-48%-44%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$10.24B	$9.96B	$10.38B	$10.64B	$10.97B	$10.36B	$11.14B	$11.37B	$11.46B	$11.16B	$12.59B	$13.01B
Cost of revenue	$4.56B	$4.46B	$4.60B	$4.70B	$4.94B	$4.47B	$4.85B	$5.08B	$4.92B	$4.89B	$5.33B	$5.63B
Gross profit	$5.69B	$5.50B	$5.77B	$5.94B	$6.03B	$5.89B	$6.29B	$6.29B	$6.54B	$6.27B	$7.27B	$7.39B
Gross margin	55.5%	55.2%	55.6%	55.8%	55.0%	56.9%	56.4%	55.4%	57.0%	56.2%	57.7%	56.8%
Research & development	$700.00M	$684.00M	$698.00M	$713.00M	$749.00M	$716.00M	$725.00M	$766.00M	$735.00M	$767.00M	$892.00M	$920.00M
Selling, general & admin	$2.72B	$2.96B	$2.94B	$2.90B	$2.91B	$3.06B	$3.09B	$3.05B	$3.13B	$3.74B	$4.03B	$4.27B
Operating income	$1.78B	$1.39B	$1.67B	$1.86B	$1.91B	$1.69B	$2.05B	$2.06B	$2.25B	$1.35B	$1.69B	$1.36B
Operating margin	17.4%	13.9%	16.1%	17.5%	17.4%	16.3%	18.4%	18.1%	19.6%	12.0%	13.4%	10.4%
Interest expense	$159.00M	$141.00M	$140.00M	$142.00M	$136.00M	$131.00M	$121.00M	$121.00M	$120.00M	$174.00M	$351.00M	$350.00M
Pre-tax income	$1.80B	$1.44B	$1.61B	$1.94B	$2.03B	$1.78B	$2.15B	$2.18B	$2.36B	$1.45B	$1.52B	$1.23B
Income tax	$201.00M	$211.00M	$305.00M	$294.00M	$-7.20B	$453.00M	$371.00M	$536.00M	$582.00M	$372.00M	$596.00M	$311.00M
Net income	$1.59B	$1.23B	$1.30B	$1.65B	$9.23B	$1.33B	$1.78B	$1.64B	$1.78B	$1.08B	$928.00M	$920.00M
Net margin	15.6%	12.3%	12.5%	15.5%	84.1%	12.8%	16.0%	14.5%	15.5%	9.6%	7.4%	7.1%
EPS (diluted)	—	$0.70	$0.74	$0.94	—	$0.76	$1.01	$0.94	—	$0.61	$0.53	$0.53

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$30.58B$17.87B$2.37B

FY18

$31.90B$18.67B$3.69B

FY19

$34.61B$19.61B$4.50B

FY20

$43.08B$24.54B$7.07B

FY21

$43.65B$24.51B$6.93B

FY22

$40.11B$22.13B$5.72B

FY23

$41.95B$23.24B$13.40B

FY24

$44.33B$25.01B$6.52B

FY25

Revenue · YoY (vs a year ago)

—+4.3%+8.5%+24%+1.3%-8.1%+4.6%+5.7%

Net income · YoY (vs a year ago)

—+56%+22%+57%-2.0%-17%+134%-51%

RevenueGross profitNet incomeLine = trend

$1.33

FY18

$2.06

FY19

$2.50

FY20

$3.94

FY21

$3.91

FY22

$3.26

FY23

$7.64

FY24

$3.72

FY25

EPS (diluted) · YoY (vs a year ago)

—+55%+21%+58%-0.8%-17%+134%-51%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$30.58B	$31.90B	$34.61B	$43.08B	$43.65B	$40.11B	$41.95B	$44.33B
Revenue growth	—	4.3%	8.5%	24.5%	1.3%	-8.1%	4.6%	5.7%
Cost of revenue	$12.71B	$13.23B	$15.00B	$18.54B	$19.14B	$17.98B	$18.71B	$19.32B
Gross profit	$17.87B	$18.67B	$19.61B	$24.54B	$24.51B	$22.13B	$23.24B	$25.01B
Gross margin	58.4%	58.5%	56.6%	57.0%	56.1%	55.2%	55.4%	56.4%
Research & development	$2.30B	$2.44B	$2.42B	$2.74B	$2.89B	$2.74B	$2.84B	$2.94B
Selling, general & admin	$9.74B	$9.77B	$9.70B	$11.32B	$11.25B	$10.95B	$11.70B	$12.33B
Operating income	$3.65B	$4.53B	$5.36B	$8.43B	$8.36B	$6.48B	$6.83B	$8.05B
Operating margin	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%
Interest expense	$826.00M	$670.00M	$546.00M	$533.00M	$558.00M	$637.00M	$559.00M	$493.00M
Pre-tax income	$2.87B	$4.08B	$4.97B	$8.21B	$8.31B	$6.66B	$7.01B	$8.47B
Income tax	$539.00M	$390.00M	$497.00M	$1.14B	$1.37B	$941.00M	$-6.39B	$1.94B
Tax rate	18.8%	9.6%	10.0%	13.9%	16.5%	14.1%	-91.1%	22.9%
Net income	$2.37B	$3.69B	$4.50B	$7.07B	$6.93B	$5.72B	$13.40B	$6.52B
Net margin	7.7%	11.6%	13.0%	16.4%	15.9%	14.3%	31.9%	14.7%
EPS (diluted)	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64	$3.72

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$30.52B$19.37B$4.09B

FY18

$31.09B$17.94B$4.14B

FY19

$32.78B$18.53B$7.15B

FY20

$35.80B$18.05B$10.25B

FY21

$36.69B$16.77B$10.17B

FY22

$38.60B$14.68B$7.28B

FY23

$47.66B$14.13B$7.97B

FY24

$52.13B$12.93B$8.94B

FY25

Shareholders' equity · YoY (vs a year ago)

—+1.8%+5.5%+9.2%+2.5%+5.2%+23%+9.4%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$3.84B	$3.86B	$6.84B	$9.80B	$9.88B	$6.90B	$7.62B	$8.52B
Short-term investments	$242.00M	$280.00M	$310.00M	$450.00M	$288.00M	$383.00M	$351.00M	$417.00M
Current assets	$14.63B	$15.67B	$20.44B	$24.24B	$25.22B	$22.67B	$23.66B	$26.00B
Total assets	$67.17B	$67.89B	$72.55B	$75.20B	$74.44B	$73.21B	$81.41B	$86.71B
Current liabilities	$9.01B	$10.86B	$11.91B	$13.11B	$15.49B	$13.84B	$14.16B	$16.50B
Long-term debt	$19.36B	$16.66B	$18.53B	$17.30B	$14.52B	$13.60B	$12.63B	$9.90B
Short-term debt	$7.00M	$1.28B	$7.00M	$754.00M	$2.25B	$1.08B	$1.50B	$3.03B
Total debt	$19.37B	$17.94B	$18.53B	$18.05B	$16.77B	$14.68B	$14.13B	$12.93B
Shareholders' equity	$30.52B	$31.09B	$32.78B	$35.80B	$36.69B	$38.60B	$47.66B	$52.13B
Current ratio	1.62	1.44	1.72	1.85	1.63	1.64	1.67	1.58
Debt / equity	0.63	0.58	0.57	0.50	0.46	0.38	0.30	0.25
Return on equity	7.8%	11.9%	13.7%	19.8%	18.9%	14.8%	28.1%	12.5%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$6.30B$4.91B$2.21B

FY18

$6.14B$4.50B$2.99B

FY19

$7.90B$5.72B$2.96B

FY20

$10.53B$8.65B$5.50B

FY21

$9.58B$7.80B$7.10B

FY22

$7.26B$5.06B$4.78B

FY23

$8.56B$6.35B$5.13B

FY24

$9.57B$7.40B$5.01B

FY25

Operating cash flow · YoY (vs a year ago)

—-2.6%+29%+33%-9.0%-24%+18%+12%

Free cash flow · YoY (vs a year ago)

—-8.3%+27%+51%-9.8%-35%+26%+16%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$6.30B	$6.14B	$7.90B	$10.53B	$9.58B	$7.26B	$8.56B	$9.57B
Capital spending	$-1.39B	$-1.64B	$-2.18B	$-1.89B	$-1.78B	$-2.20B	$-2.21B	$-2.17B
Free cash flow	$4.91B	$4.50B	$5.72B	$8.65B	$7.80B	$5.06B	$6.35B	$7.40B
FCF margin	16.0%	14.1%	16.5%	20.1%	17.9%	12.6%	15.1%	16.7%
Stock-based pay	$477.00M	$519.00M	$546.00M	$640.00M	$685.00M	$644.00M	$673.00M	$664.00M
Cash from investing	$-1.36B	$-1.82B	$-2.22B	$-2.01B	$-1.74B	$-3.13B	$-2.34B	$-2.42B
Cash from financing	$-10.39B	$-4.29B	$-2.78B	$-5.49B	$-7.64B	$-7.09B	$-5.40B	$-6.31B
Dividends paid	$-1.97B	$-2.27B	$-2.56B	$-3.20B	$-3.31B	$-3.56B	$-3.84B	$-4.12B
Share buybacks	$-238.00M	$-718.00M	$-403.00M	$-2.30B	$-3.80B	$-1.23B	$-1.30B	$-893.00M

About

About Abbott Laboratories

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Abbott Laboratories
Ticker: ABT
Exchange: NYSE
ISIN: US0028241000
SEC CIK: 0000001800
Sector: Healthcare
Industry: Medical Specialties
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: Illinois
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 20 Feb 2026
CEO: Robert B. Ford
Chair: Robert B. Ford
Headquarters: North Chicago
Address: 100 Abbott Park Road, Abbott Park, Il 60064-3500
Founded: 1888
Employees: 115,000
Trades in: US dollars (USD)
Website: abbott.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Abbott Laboratories

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers